About this trial
This study is a prospective, randomized controlled, single-blind, multicenter study design. To evaluate the safety and efficacy of traditional pulmonary vein isolation (PVI) alone and PVI combined with Bachmann bundle ablation on persistent atrial fibrillation.
According to the treatment strategy, they were divided into two groups. Control group: circumferential PVI alone group (CPVI). Experimental group: CPVI combined with Bachmann bundle ablation group (CPVI-BBM).
Eligibility criteria
Qualifiers
Subjects≥ 18 years old and ≤ 75 years old;
the subject was diagnosed with persistent atrial fibrillation (duration of ≥6 months and ≤ 3 years);
Able to understand the purpose of the trial, voluntarily participate in this study, the subject or his legal representative signed the informed consent form, and was willing to complete the follow-up according to the requirements of the protocol.
Disqualifiers
Previous atrial fibrillation catheter ablation therapy, left atrial appendage closure or atrial fibrillation surgery;
atrial fibrillation secondary to electrolyte imbalances, thyroid disease or other reversible disease, or non-cardiac causes;
Left atrial or left atrial appendage thrombus (confirmed by esophageal ultrasound or CT examination);
Patients with pulmonary vein stenosis or pulmonary vein stents implanted;
Trial design
Treatments tested in this trial
- Traditional pulmonary vein isolation (PVI) ablation
- Bachmann bundle modification